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In schizophrenia, dopaminergic hyperactivity in the mesolimbic regions, or possibly even selectively so in
the dorsal striatum, seems to cause the emergence of psychotic symptoms, whereas dopaminergic hypoac-
tivity in cortical regions underlies the negative symptoms and cognitive deficits. Managing the negative
symptoms is a major current challenge in the treatment of schizophrenia with a dearth of novel modal-
ities to address this clinical issue. Cariprazine is a novel second-generation antipsychotic that specifically
targets the D3 receptor mainly associated to negative symptoms. The review summarizes the main issues
regarding negative symptom management and the role of cariprazine treatment.
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Dopamine (DA) is a key brain neurotransmitter that contributes to control of different functions, such as cognition,
motivation and rewards, as well as locomotion [1–3]. Alterations in dopaminergic function represent a hallmark
in numerous mental diseases, including schizophrenia. The role of DA in schizophrenia is dual: on the one side,
dopaminergic hyperactivity, traditionally located in the mesolimbic regions, seems to cause emergence of psychotic
symptoms, although more recent data implicate hyperdopaminergia in the dorsal striatum [3]; on the other side,
dopaminergic hypoactivity in cortical regions underlies the negative symptoms and cognitive deficits. Primary and
enduring negative symptoms are a core feature of schizophrenia, and patients presenting with negative symptoms
account for a distinct clinical subpopulation [4]. Both the diagnosis and management of negative symptoms are
still challenging [5]. Cariprazine is a novel second-generation antipsychotic that specifically targets the D3 receptor
that is involved in the pathophysiology of negative symptoms of schizophrenia and represents a novel therapeutic
opportunity to treat this subpopulation of patients [6]. Cariprazine was approved in 2015 by US FDA for the
treatment of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder, and in 2017 by
EMA for the same indications.
The review summarizes the main issues regarding negative symptom management and the role of cariprazine
treatment.
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Table 1. Main ‘A’s that define negative symptoms.
Anhedonia Inability to experience pleasure
Avolition Lack of energy and a seeming absence of interest in routine activities
Asociality Severe impairments in social relationships
Alogia A negative thought disorder occurring with poverty of speech and content
Affective flattening Markedly decreased emotional response to a stimulus
Patient functioning & social recovery in early psychosis
In a modern community-orientated mental health service, between 30 and 60% of all patients with first-episode
psychosis experience a good outcome – namely, full interepisodic remissions, good symptomatic and social outcome,
good occupational outcome, and good global functioning – at 3 years, as reported in the Costed study [7]. This
analysis, which compared the determinants of outcome of severe mental disorders in the Nottingham cohort
(1980–1982) and the cohort treated in 1995–1997, was aimed to assess the 3-year outcome of an inception cohort
of first-episode psychoses treated in a modern, community-oriented service and to compare outcomes with an
earlier cohort treated in hospital-based care [7]. Similar proportions of two cohorts were in remission at the time
of follow-up but a higher proportion of the determinants of outcome of severe mental disorders cohort was in
hospital; patients in the cohort treated in 1995–1997 had higher rates in the three component of disability (average
disability, role handicap and social disability), indicating serious dysfunction in the majority of cases [7]. The move
from institutional to community care that occurred between the two studies had, therefore, unfortunately neither
improved clinical outcomes nor diminished the level of disability. These data are consistent with a meta-analysis
of 50 years of research indicating that recovery rates in schizophrenia, that were at a median of 13.5% had not
improved during this observation period [8]. Although the reasons for this apparent worsening of disability were not
clear, several social changes that occurred in the intervening period, such as fragmentation of social networks, greater
demands on people seeking work, easier availability of illicit drugs and failure to provide adequate recovery-based
care in the community, might all have contributed to this [7].
Early intervention is crucial to improving outcomes, with early intervention in psychosis (EIP) services now
being well-established in England and many other parts of the world. The UK’s Schizophrenia Commission report
concluded that the development of EIP was the most positive development in mental health services since the
beginning of community care [9]. One example of such an EIP is the National Institute of Mental Health-funded
Recovery After an Initial Schizophrenia Episode – Early Treatment Program (RAISE-ETP) study that compared
the 2-year outcomes of a comprehensive program – emphasizing continued antipsychotic medications, resiliency-
focused training, family education/support and vocational/educational recovery – versus usual community care,
for the first episode of psychosis [10]. Results of this study indicated that there was an improvement in both QoL
and the Positive and Negative Syndrome Scale (PANSS) total score as well as treatment engagement, depressive
symptoms and percent of time being at work or in education with comprehensive care. The effect on QoL and
PANSS total score was significantly more evident when the duration of untreated psychosis was <74 weeks, thus
supporting the importance to get disease control as soon as possible [10]. Furthermore, early intervention reduces the
long-term suicide rate [11] and long-term full functional recovery is predicted by functional and vocational recovery
at 12 months [12]. EIP were found to be significantly superior in a meta-analysis of ten studies (n = 2076) over
usual care on all meta-analyzable outcomes [13]. Main predictors of functional recovery in first-episode psychosis
appear to be shorter duration of untreated psychosis, lower scores on most cognitive variables and concurrent
remission of positive and negative symptoms [14]. Negative symptoms are common and associated with adverse
clinical outcomes [15], and they account for much of the social, occupational and interpersonal handicaps related to
schizophrenia [16,17]. Even in youth with early onset psychosis, the presence of negative symptoms at first episode
was significantly associated with multiple treatment failures [18].
Negative symptoms in schizophrenia: how to recognize & manage them
Negative symptoms are related to all three domains of schizophrenia – emotions, cognition and behavior – and
include avolition, alogia, anhedonia, affective flattering as well as asociality (Table 1) [19]. Negative symptoms
appear early during the course of illness, especially during prodromal phases, and related deficiencies persist when
schizophrenia progresses, and positive symptoms occur [5]. Negative symptoms may be measured, for example, by
PANSS or the Negative Symptom Assessment-4 that focuses on the measurement of restricted speech quality, low
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emotional expression, reduced social drive and reduced interests [20]. Additional rating scales developed to capture
more of the social aspects pertaining to negative symptoms, include the Brief Negative Symptom Scale and Clinical
Assessment Interview for Negative Symptoms [21]. However, there is currently no consensus in the filed as to which
rating scale captures negative symptoms the best and is most sensitive to change.
To correctly diagnose primary negative symptoms, it is essential to rule out the presence of other mental con-
ditions including mental retardation, dementia, depression, anxiety, substance misuse, paranoia, pharmacological
side effects such as extrapyramidal symptoms and sedation, physical conditions like sleep apnea, chronic pain, and
environmental factors such as hospitalization and social deprivation, that each can mimic secondary negative
symptoms [5]. In the CATIE study, almost 40% of the entire population had clinically relevant negative symptoms,
considering that 18.9% of patients had prominent negative symptoms and 20.9% had prominent positive and
negative symptoms; among remnant patients, 20.4% had prominent positive symptoms, and 28.7% had neither
prominent positive nor prominent negative symptoms [4]. Negative symptoms mainly affect the functional per-
formance and the patient’s likelihood to perform everyday skills, particularly social interaction, but they do not
modify as much the functional capacity that is mainly driven by cognitive performance [22–24].
Current options to treat schizophrenia are first- and second-generation antipsychotics that mostly improve
positive symptoms, but generally do not significantly ameliorate cognitive functioning and negative symptoms,
except for those secondary to relevant/untreated positive symptoms [25]. Even after psychotic symptoms are very
well controlled and general functioning is restored, neurocognition and negative symptoms must be managed as
effectively as possible in order to achieve full outcomes desired [26]. However, despite the availability of treatments
having statistically significant effects on negative symptoms in meta-analysis (second-generation antipsychotics,
antidepressants, glutamatergic medications and combinations of pharmacological with psychological interventions),
the average improvements are probably too small to be clinically meaningful [27].
The recent approval of additional partial DA agonist second-generation antipsychotics including cariprazine, may
offer both a novel therapeutic opportunity to manage negative symptoms and a pharmacological tool to investigate
further the pathophysiology of dopaminergic transmission involved in negative and cognitive symptomatology
associated with schizophrenia.
Alterations of D3 receptor-mediated transmission in schizophrenia
Cloned for the first time in 1990, the D3 receptor, a membrane receptor coupled with inhibitory protein G, shows a
localized distribution in the brain, in other words, higher in the ventral part of the caudate putamen and the frontal
cortex, which potentially reflects its role in limbic brain functions and its involvement in several psychiatric disorders
including schizophrenia [28]. The affinity of DA for this receptor is higher than for D2 receptor. Asymmetric synapses
at the head of dendritic spines in medium-sized spiny neurons of the striatum and nucleo accubens surprisingly
showed D3 receptor immunoreactivity [28]. These synapses are constituted with edges of glutamatergic terminals
distantly located from DA terminals; therefore, D3 receptors is involved in a particular mechanism of transmission,
in which DA is released in the interstitial space where it is diluted, to activate postsynaptic receptors of distal
nondopaminergic synapses. This modality of activation is possible thanking to the higher affinity of DA to the D3
receptors than to other DA receptor subtypes [29]. Furthermore, the D3 receptor seems to be less sensitive to rapid
(i.e., phasic changes on a second time scale) than to slower (i.e., tonic changes on a minute to hour range) changes
in synaptic DA concentrations [30]. Phasic DA release from mesolimbic DA neurons determines behaviorally salient
responses, whereas tonic release affects the amplitude of these responses [30], therefore an amplified D3 receptor
sensitivity would lead to aberrant salience, which is supposed to be present in schizophrenia [28]. In mouse models
mimicking both positive and negative symptoms treated with D3 receptor antagonists, it seems that blocking
the D3 receptor generates antipsychotic-like effects. Based on these evidence, a hypothetical role of D3 receptor
antagonists in contributing to restoring the glutamate/GABA homeostasis in the prefrontal cortex, and a normal
glutamate signal in projecting subcortical areas such as the striatum and nucleus accumbens has been proposed
(Figure 1) [28].
Most theories about clinical manifestations of schizophrenia and their treatment postulate an imbalance of DA
and glutamate/GABA neurotransmissions, leading to uncontrolled excitatory activity in the prefrontal cortex.
Presynaptic dopaminergic function is increased in the striatum of schizophrenic patients. This issue has led to the
theory of the ‘sensitized state’ in schizophrenia. Nevertheless, lack of DA in the prefrontal cortex is an important
feature of the disease, as shown in a MRI study demonstrating that functional connectivity of ventral tegmental
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Figure 1. Schematic representation of potential mechanism of action of D3 receptor-selective antagonists. Based on
antipsychotic-like effects observed in mouse models mimicking both positive and negative symptoms, this
hypothetical model postulated that a D3 receptor antagonist may interfere with glutamate at the level of
asymmetrical synapses in the nucleus accumbens (A), or regulate dopamine neuron activity in the VTA, through
regulation of GABA release by striato-nigral GABA terminals which express D3 receptors (B), thus normalizing
dopamine release in the prefrontal cortex (cortex) (C).
DA: Dopamine; Glu: Glutamate; VTA: Ventral tegmental area.
Reproduced with permission from [28].
Table 2. Inhibition constant of partial agonists and olanzapine versus D2 and D3 receptors.





ki (nM): Inhibition constant.
area neurons, the main source of meso-cortico-limbic DA, is damaged in schizophrenia and replaced by antipsychotic
medication [31].
Pharmacological profile of partial agonists & unique features of cariprazine
Cariprazine is a piperazine derivative, belonging with aripiprazole and brexpiprazole to the family of partial DA
agonist second-generation antipsychotics [1]. These partial DA agonists have high affinity for D2 and D3 receptors
and 5-HT1A receptors, as well as show antagonistic activity on 5-HT2A receptors. Low or null affinity has been
detected for histaminergic H1 receptors and α-adrenergic receptors [32].
The binding affinity of cariprazine for the D2 receptor is 1000-fold higher than DA (Ki cariprazine 0.49 nM,
Ki DA 540 nM), similar to brexpiprazole and tenfold higher than aripiprazole (Table 2) [24,33,34].
The affinity of cariprazine to D3 is higher than that of DA itself, which is not true for any available drug so
far. Moreover, in the living brain where DA is present, only cariprazine has the capacity to replace DA at the D3
receptors [32].
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Figure 2. Schematic representation of dopaminergic signal in healthy and pathologic condition, in which the
hypothetical role of cariprazine is highlighted.
DA: Dopamine; Glu: Glutamate; VTA: Ventral tegmental area.
Reproduced with permission from [1].
The specificity for D2 and D3 receptors and the lack of binding affinity for D1 and D4 receptors well differentiates
cariprazine from haloperidol that has similar binding activity on D2 receptors, but tenfold lower affinity for D3
receptor [32].
The high affinity for D3 receptor represents the main pharmacological feature of cariprazine that distinguishes it
from other available antipsychotics, which was demonstrated in vitro with purified proteins and in animal models,
having been confirmed in human imaging studies [35]. A positron emission tomography imaging study performed
in patients with schizophrenia demonstrated that after 2 weeks of treatment with 1 mg/day of cariprazine, the
occupancies were 76% for D3 and 45% for D2, suggesting selectivity for D3 over D2 receptors even at lower doses
than that recommended in clinical practice (1.5–6 mg/day) [35].
Compared with healthy controls, and in schizophrenia, D3 receptors are overexpressed in the dopaminergic
neurons projecting from the ventral tegmental area to the cortex and inhibit DA release in the prefrontal cortex,
thus eventually reducing glutamatergic signaling; by acting as partial agonist at the dopaminergic D3 receptors of
the mesocortical pathways, cariprazine may reduce the ‘pathologic’ inhibition and may contribute to normalize DA
release within the prefrontal cortex. This hypothetical mechanism of action of cariprazine is depicted on Figure 2 [1].
Long-term treatment with cariprazine induces an increased expression of D3 receptor in the forebrain, and this
effect seems to be unique, since other antipsychotic agents such as haloperidol, fluphenazine, clozapine, olanzapine,
risperidone and asenapine, do not alter D3 receptor levels [1]. Upregulation of dopaminergic receptors is usually
observed with antagonist agents; despite its activity as partial agonist, cariprazine increased D3 receptors, thus
suggesting that it can act as an antagonist in vivo [1].
In addition to its effect on dopaminergic signaling, cariprazine increases 5HT1a receptor levels in the cerebral
cortex, but does not alter 5HT2a levels, differently from other antipsychotic drugs that generally modify the
expression of both receptors [1].
Cariprazine is safe and effective at the dose range of 1.5–6 mg daily. It is mainly metabolized by CYP3A4 (and, to
a lesser extent, CYP2D6), generating two active metabolites: desmethyl cariprazine and di-desmethyl cariprazine.
The steady state is reached around weeks 1–2 for cariprazine and desmethyl cariprazine and around weeks 4–8 for
di-desmethyl cariprazine [36]. By comparison, aripiprazole and brexpiprazole also have long half-lives, but they and
their active metabolites have half-lives of 3–4 days, not weeks [32].
The very long half-life for cariprazine has two important clinical consequences: since cariprazine takes about five
half-lives to get to steady state, it means that the total cariprazine (especially of di-desmethyl cariprazine) exposure
is rising for many weeks after initiating a dose, even if the daily dose stays the same. Second, after discontinuing, it
will take many weeks before the active drug is washed out – a potential advantage for schizophrenia patients who
frequently show poor compliance [32].
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Cariprazine activity from clinical trials to practice
Nemeth and colleagues conducted the hallmark study on the role of cariprazine in improving negative symptoms in
patients with schizophrenia [37]. In this study, cariprazine was compared with risperidone in patients with persistent
predominant negative symptoms. The study population consisted of patients with stable illness for at least 6 months
– without any hospitalization or acute exacerbation – and a high PANSS-Factor Score for Negative Symptoms
(FSNS), consisting of a total score of 24 or more score and a rating of at least moderate on at least two of three
core negative symptoms. Altogether, 461 patients were randomized to receive double-blind cariprazine 4.5 mg/day
(range = 3–6 mg) or risperidone 4 mg/day (range = 3–6 mg) for 26 weeks. Both agents significantly improved
the PANSS-FSNS after 26 weeks of treatment, but from week 14 onwards and at all other time points afterward,
cariprazine was statistically superior to risperidone in ameliorating negative symptoms. The reduction of negative
symptoms was not due to greater improvement with cariprazine versus risperidone in positive symptoms, depression
or differences in extrapyramidal side effect ratings, ruling out pseudospecificity of the superiority of cariprazine
over risperidone for negative symptoms. Additionally, cariprazine improved personal and social functioning more
than risperidone, already starting from the week 9 of treatment, which preceded the significant difference from
risperidone observed for negative symptoms [37].
The clinical relevance of the superiority of cariprazine versus risperidone was not only indicated by the im-
provement of functioning, but also a greater proportion of patients who responded to treatment, defined as a
≥20% decrease in PANSS-FSNS (69 vs 58%) [37]. The corresponding number to treat (NNT) for cariprazine was
nine (meaning that after each nine patients treated with cariprazine, one patient more than with risperidone would
be a treatment responder), whereby an NNT ≤10 is considered clinically relevant as per NICE guidelines [38].
Similarly, defining treatment response by a CGI improvement score of much or very improved, cariprazine achieved
treatment response in 48 versus 34% of patients with risperidone, translating into an NNT of seven. On the Per-
sonal and Social Performance Scale, cariprazine showed superiority in the self-care score, socially useful activities
score and personal/social relationship score [37]. In summary, in patients with persistent prominent negative symp-
toms and stabilized for at least 6 months, cariprazine was beneficial in improving personal and social functioning,
starting from the 9th week and the treatment was clinically relevant in improving persistent negative symptoms
and functioning (Figure 3).
The overall efficacy of cariprazine in the acute phase of schizophrenia has been demonstrated in pivotal trials
and in the subsequent meta-analysis [39–42]. Using PANSS individual items and PANSS derived factors from pivotal
studies results, a post hoc analysis examined the effect of cariprazine in negative symptoms and confirmed the
results reported by Nemeth et al. [37]. The negative symptom improvements were statistically significant in favor of
cariprazine versus risperidone on items N2 (emotional withdrawal) and N4 (passive/apathetic social withdrawal)
and in avolition/social amotivation and expressive deficit factors. The mean changes in positive symptoms were
observed at week 26, thus indicating the specificity of the negative symptom changes. Indeed, changes in negative
symptoms were not secondary to other domains such as depression/anxiety, uncontrolled excitement/hostility and
positive symptoms [43]. Furthermore, a post hoc analysis from short-term pivotal studies described also the effects
of cariprazine on hostility associated with schizophrenia and indicated that cariprazine significantly improved the
hostility item versus placebo, and this effect increased with greater levels of baseline hostility [44].
Cariprazine (1.5–3.0 and 4.5–6.0 mg/day) was statistically superior versus placebo, but not versus aripiprazole
and risperidone (in this case after adjusting for positive symptoms, correction for pseudospecificity), in a subset of
patients with relevant negative symptoms, in other words, PANSS-FSNS ≥24, PANSS-Factor Score for Positive
Symptoms ≤19 and scores of ≥4 on ≥2 of three PANSS items (blunted affect [N1], passive/apathetic social
withdrawal [N4] and lack of spontaneity/flow of conversation [N6]) in the acute phase of two randomized clinical
trials [45].
Long-term treatment with cariprazine can prevent relapse in schizophrenic patients (Figure 4) [46–48]. Based on
data from randomized clinical trials, stopping cariprazine may delay the incidence of schizophrenia relapse and the
drug could be considered as a long acting oral medication.
Concerning safety, cariprazine within the FDA-recommended dose range of 1.5–6 mg/day for schizophrenia
has shown to be safe and well tolerated in a pooled analysis of long-term, open-label, flexible-dose studies (RGH-
MD-11 and RGH-MD-17) in patients who received at least one dose of cariprazine (safety population) during
the open-label extension period. In this study, treatment-emergent adverse events of akathisia, insomnia, weight
increased and headache were reported in more than 10% of patients. Changes in serum chemistry and hematology
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Figure 3. Mean change from baseline to week 6 in the Positive and Negative Syndrome Scale factors (pooled
intent-to-treat population).
Error bars display the standard error of the LS mean.
**p < 0.01; ***p < 0.001.
ES: Effect size; LS: Least squares; LSMD: LS mean difference.
This image has been reproduced from a paper previously published under the CC-BY-NC-ND license [39].
Placebo (n = 99)





















































Figure 4. 6-month sustained remission rates during the double-blind phase, considering patients who met
symptomatic remission criteria and various time component criteria with cariprazine and placebo.
NNT: Number to treat.
Reproduced with permission from [47].
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parameters were not clinically meaningful; mean prolactin levels decreased in all dose groups [49]. Furthermore, in a
1-year, open-label study, cariprazine used even at higher doses than that recommended (3–9 mg/day) ameliorated
overall symptomatology, without reporting unexpected safety issues or deaths. Triglycerides and cholesterol, as well
as QTc decreased, and indicating that cariprazine was safe, including in the important areas of cardiometabolic and
cardiac health [50].
In a large network meta-analysis of 402 randomized controlled trials combining direct and indirect comparisons
in a Bayesian hierarchical model, 132 studies (33%) with 32,015 (60%) participants reported usable results for
negative symptoms (21 antipsychotics). The effect size of cariprazine was -0.32 (95% CI: -0.44 to -0.20), while other
drugs such as clozapine, amisulpride and olanzapine showed the highest effects in reducing these symptoms [51].
However, since all of the trials in this network meta-analysis were short-term studies in acutely exacerbated patients
with schizophrenia, much of the reduction of the negative symptoms is likely to have been secondary to positive
symptom reduction, raising the issue of pseudospecificity and requiring dedicated negative symptoms studies with
adequate design features.
Therapeutic goal of the long-term treatment of schizophrenia
Recently, schizophrenia care has become influenced by the term P4 medicine, which stands for predictive, preventive,
personalized and participatory. All treatments and other services should be optimized for each individual in order
to improve the recovery, intended as vocational and/or educational functioning, independent living, better physical
health, instrumental competence, social integration and improved QoL [52]. However, in clinical practice, only a
small portion of patients with schizophrenia achieves recovery [53]. One way to try overcome such overall poor
outcomes is to match different pharmacological properties to individual patient needs, and to select antipsychotic
therapy based on different efficacy and tolerability profiles, individual patient characteristics and preference that
may influence the choice of pharmacological action of the treatment. Multiple meta-analyses have indicated that
the efficacy differences between antipsychotics (excluding clozapine) are relatively small [54,55], while tolerability








































































































Figure 5. Heat map of antipsychotic drugs ranked according to associated degree of alteration in body weight, BMI and metabolic
parameters. Numbers reflect p-value, which rank antipsychotics on a continuous scale from 0 to 1. A higher p-value indicates a greater
increase in the metabolic parameter, with the exception of HDL cholesterol, for which a higher p-value indicates a smaller increase. Grey
squares indicate that data were not available. Cariprazine showed low risk in increasing cholesterol and triglycerides and greater risk in
increasing weight.
HDL: High-density lipoprotein; LDL: Low-density lipoprotein.
This image has been reproduced from a paper previously published under the CC-BY license [58].
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medications are quite different. In this context, it is important to consider that the estimated prevalence and relative
risk of modifiable cardiovascular disease risk factors is one- to five-times greater in patients with schizophrenia
compared with the general population [56] and that some antipsychotics differentially increase the risk for insulin
resistance and obesity [57]. As other partial DA agonist second-generation antipsychotics, cariprazine shows neutral
or low effects on weight gain and lipid and/or glucose abnormalities (Figure 5) [57,58].
Conclusion & future perspective
Cariprazine represents a good therapeutic option since it is beneficial in improving negative symptoms in both
the acute and long-term setting. In addition, cariprazine can effectively control positive symptoms and reduce the
frequency of relapse, thus suggesting that it can be used as first-line therapy. Its unique pharmacological profile
based on high affinity on D2 and, especially, D3 receptor, partial DA agonist activity, and low/absent affinity for
histaminergic and cholinergic receptors may contribute to the observed efficacy for negative symptoms and low
rates of adverse events, including the important metabolic and cardiac side effects. The long, combined half-life
of cariprazine and its active metabolites may further allow for a longer maintenance of therapeutic blood levels
during intermittent, partial or even full nonadherence. Additional comparative data would be helpful to characterize
efficacy, effectiveness and safety of cariprazine more fully versus other available antipsychotics.
Executive summary
Patient functioning & social recovery in early psychosis
• Early intervention is crucial to improving outcomes.
• Negative symptoms are common and associated with adverse clinical outcomes.
• Negative symptoms account for much of the social, occupational and interpersonal dysfunction related to
schizophrenia.
Negative symptoms in schizophrenia: how to recognize & manage them
• Negative symptoms are related to all three domains of schizophrenia – emotions, cognition and behavior.
• To correctly diagnose primary negative symptoms, it is essential to rule out the presence of other mental
conditions and adverse medication effects that can mimic negative symptoms.
• Neurocognition and negative symptoms must be managed as effectively as possible to maximize the achievement
of the desired outcomes.
The role of the D3 receptor in schizophrenia
• Among the D1–D5 dopaminergic receptors, the D3 receptor has been specifically associated with negative
symptoms of schizophrenia.
Pharmacological profile of partial dopamine agonists & unique features of cariprazine
• Cariprazine is a piperazine derivative, belonging with aripiprazole and brexipiprazole to the family of partial
dopamine agonist second-generation antipsychotics.
• Cariprazine may help normalize dopamine release within the prefrontal cortex.
• Cariprazine is safe and effective at the dose range of 1.5–6 mg daily.
Cariprazine activity from clinical trials to practice
• In patients with persistent predominant negative symptoms and stabilized for at least 6 months, cariprazine was
beneficial in improving negative symptoms, global clinical illness severity as well as personal and social
functioning.
• Long-term treatment with cariprazine can prevent relapse in schizophrenic patients.
Therapeutic goals of the long-term treatment of people with schizophrenia
• Schizophrenia care has become influenced by the term P4 medicine.
• Cariprazine shows neutral or low effects on weight gain and lipid and/or glucose abnormalities, which are
relevant outcomes both medically and regarding QoL and well-being.
Financial & competing interests disclosure
CU Correll has been a consultant and/or advisor to or has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome,
Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Med-
scape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda and Teva. He has
provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus
and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a stock option holder of
LB Pharma. A Fagiolini is /has been a consultant and/or a speaker and/or has received research grants from Allergan, Angelini,
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